MY172472A - Mice that make heavy chain antibodies - Google Patents

Mice that make heavy chain antibodies

Info

Publication number
MY172472A
MY172472A MYPI2014003004A MYPI2014003004A MY172472A MY 172472 A MY172472 A MY 172472A MY PI2014003004 A MYPI2014003004 A MY PI2014003004A MY PI2014003004 A MYPI2014003004 A MY PI2014003004A MY 172472 A MY172472 A MY 172472A
Authority
MY
Malaysia
Prior art keywords
heavy chain
mice
chain antibodies
deletion
domain
Prior art date
Application number
MYPI2014003004A
Other languages
English (en)
Inventor
Sean Stevens
Lynn Macdonald
Andrew J Murphy
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MY172472A publication Critical patent/MY172472A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MYPI2014003004A 2009-12-10 2010-12-10 Mice that make heavy chain antibodies MY172472A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28525009P 2009-12-10 2009-12-10

Publications (1)

Publication Number Publication Date
MY172472A true MY172472A (en) 2019-11-26

Family

ID=43534479

Family Applications (2)

Application Number Title Priority Date Filing Date
MYPI2014003004A MY172472A (en) 2009-12-10 2010-12-10 Mice that make heavy chain antibodies
MYPI2012002491A MY173363A (en) 2009-12-10 2010-12-10 Mice that make heavy chain antibodies

Family Applications After (1)

Application Number Title Priority Date Filing Date
MYPI2012002491A MY173363A (en) 2009-12-10 2010-12-10 Mice that make heavy chain antibodies

Country Status (24)

Country Link
US (9) US8754287B2 (enExample)
EP (3) EP2509409B1 (enExample)
JP (5) JP5909449B2 (enExample)
KR (2) KR101553244B1 (enExample)
CN (3) CN104131035A (enExample)
AU (1) AU2010328046C1 (enExample)
CA (1) CA2782936C (enExample)
CY (2) CY1118163T1 (enExample)
DK (2) DK2509409T3 (enExample)
ES (2) ES2595376T3 (enExample)
HR (1) HRP20190820T1 (enExample)
HU (2) HUE030208T2 (enExample)
IL (4) IL220150A0 (enExample)
LT (2) LT2509409T (enExample)
MY (2) MY172472A (enExample)
PL (2) PL2509409T3 (enExample)
PT (2) PT2509409T (enExample)
RS (1) RS58709B1 (enExample)
RU (1) RU2603102C2 (enExample)
SG (2) SG181477A1 (enExample)
SI (2) SI2509409T1 (enExample)
SM (1) SMT201900251T1 (enExample)
TR (1) TR201906488T4 (enExample)
WO (1) WO2011072204A1 (enExample)

Families Citing this family (163)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1978032A3 (en) 2004-07-22 2009-02-18 Erasmus University Medical Center Rotterdam Binding molecules
WO2010039900A2 (en) * 2008-09-30 2010-04-08 Aliva Biopharmaceuticals, Inc. Non-human mammals for the production of chimeric antibodies
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
CN102638971B (zh) 2009-07-08 2015-10-07 科马布有限公司 动物模型及治疗分子
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
DK2509409T3 (en) * 2009-12-10 2016-11-14 Regeneron Pharma MICE, WHICH PRODUCES HEAVY CHAIN ANTIBODIES
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
HRP20151188T4 (hr) 2010-02-08 2021-10-01 Regeneron Pharmaceuticals, Inc. Miš sa zajedničkim lakim lancem
PL3251503T3 (pl) 2010-03-31 2024-07-08 Ablexis, Llc Modyfikacja myszy metodami inżynierii genetycznej w celu wytworzenia przeciwciał chimerycznych
US10793829B2 (en) 2010-07-26 2020-10-06 Trianni, Inc. Transgenic mammals and methods of use thereof
RU2580017C2 (ru) 2010-07-26 2016-04-10 Трианни, Инк. Трансгенные животные и способы применения
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
KR102306967B1 (ko) 2010-08-02 2021-10-01 리제너론 파아마슈티컬스, 인크. Ｖｌ 도메인을 포함하는 결합 단백질을 생성하는 마우스
LT2738259T (lt) 2011-02-25 2020-03-10 Regeneron Pharmaceuticals, Inc. Adam6 pelės
US20140056897A1 (en) * 2011-03-10 2014-02-27 Hco Antibody, Inc. Bispecific three-chain antibody-like molecules
PT3865581T (pt) 2011-08-05 2024-10-04 Regeneron Pharma Murganhos da cadeia leve universal humanizada
AU2012311286B2 (en) * 2011-09-19 2018-07-26 Kymab Limited Antibodies, variable domains and chains tailored for human use
GB2501753A (en) * 2012-05-04 2013-11-06 Kymab Ltd Human antibodies
WO2013045916A1 (en) * 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
KR20140082824A (ko) * 2011-10-17 2014-07-02 리제너론 파아마슈티컬스, 인크. 제한된 면역글로불린 중쇄 마우스
CA2857645A1 (en) * 2011-11-30 2013-06-06 Wellstat Diagnostics, Llc Assays, antibodies, immunogens and compositions related to 5-fu
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
PT3527070T (pt) 2011-12-20 2025-12-19 Regeneron Pharma Murganhos de cadeia leve humanizada
KR102213535B1 (ko) 2012-03-16 2021-02-08 리제너론 파마슈티칼스 인코포레이티드 pH-민감성 면역글로불린 서열을 발현하는 비-사람 동물
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
DK2825036T3 (en) 2012-03-16 2018-07-16 Regeneron Pharma Histidine engineered light chain antibodies and genetically modified rodents to generate them
HK1200271A1 (en) 2012-03-16 2015-08-07 瑞泽恩制药公司 Mice that produce antigen-binding proteins with ph-dependent binding characteristics
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) * 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
EP2831245A1 (en) * 2012-03-28 2015-02-04 Kymab Limited Transgenic non-human vertebrate for the expression of class - switched, fully human, antibodies
EP3912464A1 (en) 2012-06-12 2021-11-24 Regeneron Pharmaceuticals, Inc. Humanized non-human animals with restricted immunoglobulin heavy chain loci
MY185881A (en) 2013-02-20 2021-06-14 Regeneron Pharma Non-human animals with modified immunoglobulin heavy chain sequences
CA2900824A1 (en) * 2013-02-22 2014-08-28 Regeneron Pharmaceuticals, Inc. Mice expressing humanized major histocompatibility complex
WO2014141192A1 (en) * 2013-03-15 2014-09-18 Erasmus University Medical Center Generation of heavy chain-only antibodies
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
CA2925723A1 (en) 2013-10-01 2015-04-09 Kymab Limited Animal models and therapeutic molecules
EP3068798B1 (en) * 2013-11-12 2020-10-07 OGD2 Pharma Human igg1 derived antibody with pro-apoptotic activity
CN106164092A (zh) 2014-03-21 2016-11-23 瑞泽恩制药公司 表现不同结合特征的vl抗原结合蛋白
CN106255410B (zh) * 2014-03-21 2020-01-10 瑞泽恩制药公司 产生单结构域结合蛋白的非人动物
RU2700484C2 (ru) * 2014-04-08 2019-09-17 Регенерон Фармасьютикалз, Инк. Не относящиеся к человеку животные, имеющие гуманизированные fc-гамма-рецепторы
AU2015271709B2 (en) 2014-06-06 2020-11-26 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
CN104177496B (zh) * 2014-09-02 2015-03-11 安源生物科技(上海)有限公司 人IgG2抗体铰链区修饰体
SG10201902924RA (en) 2014-10-03 2019-05-30 Massachusetts Inst Technology Antibodies that bind ebola glycoprotein and uses thereof
EP3461848B1 (en) * 2014-10-22 2023-10-11 Crescendo Biologics Limited Transgenic mice
TWI711630B (zh) 2014-11-21 2020-12-01 美商必治妥美雅史谷比公司 抗ｃｄ７３抗體及其用途
CN107278206B (zh) 2014-12-19 2021-04-02 雷根尼桑斯公司 结合人c6的抗体及其用途
MY187045A (en) 2014-12-23 2021-08-27 Bristol Myers Squibb Co Antibodies to tigit
US11111314B2 (en) 2015-03-19 2021-09-07 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
EA035412B1 (ru) 2015-05-29 2020-06-10 Бристол-Майерс Сквибб Компани Антитела к ox40 и их применение
US10479838B2 (en) 2015-06-29 2019-11-19 Bristol-Myers Squibb Company Antibodies to CD40 with enhanced agonist activity
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
IL257411B2 (en) * 2015-08-24 2024-05-01 Trianni Inc Enhanced production of immunoglobulins
CN105441455B (zh) * 2015-10-21 2020-08-28 重庆金迈博生物科技有限公司 一种嵌合核酸分子及其在人源化抗体制备中的应用
CA3005855A1 (en) 2015-11-19 2017-05-26 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
WO2017095939A1 (en) 2015-12-03 2017-06-08 Trianni, Inc. Enhanced immunoglobulin diversity
AU2017213633B2 (en) 2016-02-04 2023-08-03 Trianni, Inc. Enhanced production of immunoglobulins
CA3016187A1 (en) 2016-03-04 2017-09-08 Bristol-Myers Squibb Company Combination therapy with anti-cd73 antibodies
KR20180114223A (ko) 2016-03-04 2018-10-17 더 락커펠러 유니버시티 증진된 효능제 활성을 갖는 cd40에 대한 항체
EP3454864A4 (en) 2016-04-21 2021-01-13 Abbvie Stemcentrx LLC Novel anti-bmpr1b antibodies and methods of use
US10968279B2 (en) 2016-05-09 2021-04-06 Bristol-Myers Squibb Company TL1A antibodies and uses thereof
US20170332610A1 (en) 2016-05-20 2017-11-23 Regeneron Pharmaceuticals, Inc. Methods for breaking immunological tolerance using multiple guide rnas
KR102483193B1 (ko) 2016-06-03 2023-01-04 리제너론 파마슈티칼스 인코포레이티드 외인성 말단 데옥시뉴클레오타이드 전달효소를 발현하는 비인간 동물
SG11201900026TA (en) 2016-07-14 2019-01-30 Bristol Myers Squibb Co Antibodies against tim3 and uses thereof
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
KR102512934B1 (ko) 2016-08-10 2023-03-23 레전드 바이오테크 아일랜드 리미티드 Bcma를 표적으로 하는 키메라 항원 수용체 및 이들의 이용 방법
US10981976B2 (en) 2016-08-31 2021-04-20 University Of Rochester Human monoclonal antibodies to human endogenous retrovirus K envelope (HERV-K) and use thereof
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
CA3040189A1 (en) 2016-10-13 2018-04-19 Massachusetts Institute Of Technology Antibodies that bind zika virus envelope protein and uses thereof
WO2018144097A1 (en) 2016-11-04 2018-08-09 Akeagen Llc Genetically modified non-human animals and methods for producing heavy chain-only antibodies
EA201991720A1 (ru) 2017-02-17 2020-01-20 Бристол-Маерс Сквибб Компани Антитела к альфа-синуклеину и их применения
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
CN116891534A (zh) 2017-06-27 2023-10-17 瑞泽恩制药公司 向性修饰的重组病毒粒子和其用于将遗传物质靶向引入至人类细胞中的用途
WO2019000223A1 (en) 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
US20200140491A1 (en) 2017-06-27 2020-05-07 Regeneron Pharmaceuticals, Inc. Tropism-Modified Recombinant Viral Vectors and Uses Thereof for the Targeted Introduction of Genetic Material into Human Cells
JP6677277B2 (ja) 2017-07-19 2020-04-08 株式会社デンソー 車両用制御装置及び電源供給回路
JP6951545B2 (ja) 2017-07-21 2021-10-20 トリアンニ インコーポレイテッドＴｒｉａｎｎｉ，Ｉｎｃ． 単鎖ｖｈ及び重鎖抗体
JP7383617B2 (ja) 2017-12-28 2023-11-20 ナンジン レジェンド バイオテック カンパニー，リミテッド Ｐｄ－ｌ１に対する抗体及びそのバリアント
TW201930358A (zh) 2017-12-28 2019-08-01 大陸商南京傳奇生物科技有限公司 針對ｔｉｇｉｔ之單域抗體及其變異體
JP7358361B2 (ja) 2018-01-12 2023-10-10 ブリストル－マイヤーズ スクイブ カンパニー Ｔｉｍ３に対する抗体およびその使用
KR102839330B1 (ko) 2018-01-15 2025-07-30 난징 레전드 바이오테크 씨오., 엘티디. Pd-1에 대한 단일-도메인 항체 및 이의 변이체
CA3093407A1 (en) 2018-03-23 2019-09-26 Bristol-Myers Squibb Company Antibodies against mica and/or micb and uses thereof
SG11202008799PA (en) 2018-03-24 2020-10-29 Regeneron Pharma Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
WO2019190990A1 (en) * 2018-03-26 2019-10-03 Regeneron Pharmaceuticals, Inc. Humanized rodents for testing therapeutic agents
JP7346790B2 (ja) 2018-03-30 2023-09-20 ナンジン レジェンド バイオテック カンパニー，リミテッド Ｌａｇ‐３に対する単一ドメイン抗体およびその使用
WO2019227490A1 (en) 2018-06-01 2019-12-05 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and methods for imaging
WO2019228514A1 (en) 2018-06-01 2019-12-05 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and uses thereof for treating disease or condition
WO2019240999A1 (en) * 2018-06-13 2019-12-19 Crystal Bioscience Inc. Camelization of a human variable domain by gene conversion
US12428471B2 (en) * 2018-06-13 2025-09-30 Crystal Bioscience Inc. Transgenic chicken that makes antibodies with long CDR-H3S stabilized by multiple disulfide bridges and diversified by gene conversion
WO2019240998A1 (en) 2018-06-13 2019-12-19 Crystal Bioscience Inc. Production of antibodies by modification of an autonomous heavy chain variable domain by gene conversion
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
GB2576914A (en) 2018-09-06 2020-03-11 Kymab Ltd Antigen-binding molecules comprising unpaired variable domains produced in mammals
WO2020052542A1 (en) 2018-09-10 2020-03-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies against cll1 and constructs thereof
BR112021009111A2 (pt) 2018-11-16 2021-08-24 Bristol-Myers Squibb Company Anticorpos anti-nkg2a e usos dos mesmos
EP3914622A1 (en) 2019-01-22 2021-12-01 Bristol-Myers Squibb Company Antibodies against il-7r alpha subunit and uses thereof
WO2020151572A1 (en) 2019-01-23 2020-07-30 Tayu Huaxia Biotech Medical Group Co., Ltd. Anti-pd-l1 diabodies and the use thereof
CN113874386A (zh) 2019-05-24 2021-12-31 瑞泽恩制药公司 经修饰的病毒颗粒和其用途
IL293330A (en) 2019-12-02 2022-07-01 Regeneron Pharma mhc ii peptide protein structures and uses thereof
CN110818795B (zh) 2020-01-10 2020-04-24 上海复宏汉霖生物技术股份有限公司 抗tigit抗体和使用方法
EP4090762A1 (en) * 2020-01-17 2022-11-23 Becton, Dickinson and Company Methods and compositions for single cell secretomics
EP4097144A4 (en) * 2020-01-28 2024-02-28 University of Southern California Genome engineering the human immunoglobulin locus to express recombinant binding domain molecules
CN115151573A (zh) 2020-02-28 2022-10-04 上海复宏汉霖生物技术股份有限公司 抗cd137构建体、多特异性抗体及其用途
KR20220148209A (ko) 2020-02-28 2022-11-04 상하이 헨리우스 바이오테크, 인크. 항cd137 작제물 및 그 용도
CN111333719B (zh) * 2020-03-16 2021-10-01 西南大学 抗hpv16e7蛋白单抗69a6、杂交瘤细胞及其制备方法和应用
WO2021231732A1 (en) 2020-05-15 2021-11-18 Bristol-Myers Squibb Company Antibodies to garp
AU2021283345A1 (en) 2020-06-02 2023-02-02 Dynamicure Biotechnology Llc Anti-CD93 constructs and uses thereof
CN116529260A (zh) 2020-06-02 2023-08-01 当康生物技术有限责任公司 抗cd93构建体及其用途
CN116157510A (zh) 2020-06-17 2023-05-23 詹森生物科技公司 用于制造多能干细胞的材料和方法
AU2021297540A1 (en) 2020-06-24 2023-02-02 Prothena Biosciences Limited Antibodies recognizing sortilin
JP2023535345A (ja) * 2020-07-13 2023-08-17 キソジ・バイオテクノロジー・インコーポレイテッド 重鎖抗体を発現するトランスジェニック動物
WO2022012680A1 (en) 2020-07-16 2022-01-20 Nanjing Legend Biotech Co., Ltd. Cd20 binding molecules and uses thereof
US20230322935A1 (en) 2020-07-29 2023-10-12 Dynamicure Biotechnology Llc Anti-cd93 constructs and uses thereof
CA3190987A1 (en) 2020-08-10 2022-02-17 Janssen Biotech, Inc. Materials and methods for producing bioengineered virus specific lymphocytes
CN114134144A (zh) * 2020-09-04 2022-03-04 北京仁源欣生生物科技有限公司 一种非人哺乳动物或其子代的制备方法及其应用
KR20230066386A (ko) 2020-09-11 2023-05-15 리제너론 파마슈티칼스 인코포레이티드 항원 특이적 항체의 확인 및 제조
CN118146383A (zh) 2020-09-28 2024-06-07 安济盛生物医药有限公司 抗硬骨抑素构建体及其用途
WO2022116877A1 (en) 2020-12-02 2022-06-09 Shanghai Henlius Biotech, Inc. ANTI-GARP/TGFβ ANTIBODIES AND METHODS OF USE
EP4258865B1 (en) * 2020-12-09 2025-09-03 Trianni, Inc. Heavy chain-only antibodies
AU2021400584A1 (en) 2020-12-16 2023-06-29 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
US20240317849A1 (en) 2020-12-23 2024-09-26 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding anchor modified antibodies and uses thereof
KR102836733B1 (ko) 2021-02-19 2025-07-21 (주)샤페론 Pd-l1 및 cd47에 대한 이중특이적 단일 도메인 항체 및 이의 용도
WO2022177393A1 (ko) 2021-02-19 2022-08-25 (주)샤페론 Pd-l1에 대한 단일 도메인 항체 및 이의 용도
BR112023016713A2 (pt) 2021-02-19 2023-10-31 Seoul Nat Univ R&Db Foundation Anticorpo ou um fragmento de ligação ao antígeno do mesmo, molécula de ácido nucleico, métodos para produzir um anticorpo ou um fragmento de ligação ao antígeno do mesmo e para detectar agrupamento de diferenciação 47 ou determinar uma quantidade de agrupamento de diferenciação 47 em uma amostra, e, uso do anticorpo ou de um fragmento de ligação ao antígeno do mesmo
JP2024509191A (ja) 2021-03-05 2024-02-29 ダイナミキュア バイオテクノロジー エルエルシー 抗ｖｉｓｔａ構築物およびその使用
WO2022204724A1 (en) 2021-03-25 2022-09-29 Dynamicure Biotechnology Llc Anti-igfbp7 constructs and uses thereof
JP7555296B2 (ja) * 2021-03-31 2024-09-24 太平洋セメント株式会社 二酸化炭素の固定化方法
CA3218564A1 (en) * 2021-05-05 2022-11-10 Leveragen, Inc. Engineered non-human animals for producing antibodies
CN117651486A (zh) * 2021-05-05 2024-03-05 利威瑞健股份有限公司 用于生产抗体的工程改造的非人动物
US12227574B2 (en) 2021-06-17 2025-02-18 Amberstone Biosciences, Inc. Anti-CD3 constructs and uses thereof
EP4342908A4 (en) * 2021-06-17 2024-10-23 Fapon Biotech Inc. CHIMERIC IMMUNGLOBULIN
WO2022269473A1 (en) 2021-06-23 2022-12-29 Janssen Biotech, Inc. Materials and methods for hinge regions in functional exogenous receptors
US20230062964A1 (en) * 2021-08-30 2023-03-02 New York University Modified mice that produce heavy chain only antibodies
KR20240095211A (ko) 2021-11-04 2024-06-25 리제너론 파마슈티칼스 인코포레이티드 골격근에 재표적화된 바이러스 입자
AU2022408865A1 (en) 2021-12-17 2024-07-04 Shanghai Henlius Biologics Co., Ltd. Anti-ox40 antibodies, multispecific antibodies and methods of use
JP2025501522A (ja) 2021-12-17 2025-01-22 シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド 抗ｏｘ４０抗体及び使用方法
EP4482861A4 (en) * 2022-02-24 2026-05-20 A & G Pharmaceutical Inc Fully human monoclonal antibodies directed against human progranulin
CN118974096A (zh) 2022-03-25 2024-11-15 上海复宏汉霖生物技术股份有限公司 抗msln抗体及使用方法
EP4522726A1 (en) 2022-05-09 2025-03-19 Regeneron Pharmaceuticals, Inc. Vectors and methods for in vivo antibody production
US20250188492A1 (en) 2022-07-22 2025-06-12 Janssen Biotech, Inc. Enhanced Transfer of Genetic Instructions to Effector Immune Cells
EP4561598A1 (en) 2022-07-29 2025-06-04 Regeneron Pharmaceuticals, Inc. Viral particles retargeted to transferrin receptor 1
US20260078185A1 (en) 2022-09-07 2026-03-19 Dynamicure Biotechnology Llc Anti-vista constructs and uses thereof
IL319494A (en) * 2022-09-16 2025-05-01 Biocytogen Pharmaceuticals Beijing Co Ltd Genetically modified non-human animals and methods for producing heavy chain antibodies
WO2024102454A1 (en) * 2022-11-09 2024-05-16 Leveragen, Inc. Engineered non-human animals
WO2024163477A1 (en) 2023-01-31 2024-08-08 University Of Rochester Immune checkpoint blockade therapy for treating staphylococcus aureus infections
CN121039163A (zh) 2023-05-02 2025-11-28 瑞泽恩制药公司 抗人m-钙粘蛋白（cdh15）抗体、缀合物及其用于将遗传有效负载递送至肌肉细胞的用途
WO2025034806A1 (en) 2023-08-08 2025-02-13 Wisconsin Alumni Research Foundation Single-domain antibodies and variants thereof against fibroblast activation protein
EP4512243A1 (en) 2023-08-21 2025-02-26 Kymab Limited Binding molecules
CN122003435A (zh) 2023-09-03 2026-05-08 科越医药(美国)有限责任公司 包含抗因子d部分的多特异性构建体
WO2025064738A1 (en) 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Dntt 250-258 off-target peptides and uses thereof
WO2025064761A1 (en) 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Kras10-18 g12d off-target peptides and uses thereof
WO2025151796A1 (en) 2024-01-11 2025-07-17 Regeneron Pharmaceuticals, Inc. Viral particles retargeted to nervous system tissues
WO2025178959A1 (en) 2024-02-20 2025-08-28 University Of Georgia Research Foundation, Inc. Single-domain antibodies and variants thereof against tab1
US20250361320A1 (en) 2024-02-27 2025-11-27 Bristol-Myers Squibb Company Anti-ceacam5 antibodies and uses thereof
WO2026006724A1 (en) 2024-06-28 2026-01-02 Regeneron Pharmaceuticals, Inc. Prame off-target peptides and uses thereof
WO2026006734A1 (en) 2024-06-28 2026-01-02 Regeneron Pharmaceuticals, Inc. Off-target peptide-mhc complex conformation modeling systems and methods for antigen-recognition molecule development
WO2026025058A1 (en) 2024-07-25 2026-01-29 Regeneron Pharmaceuticals, Inc. Aav viral particles retargeted to egfr-expressing cancer cells
WO2026030428A2 (en) 2024-08-01 2026-02-05 Regeneron Pharmaceuticals, Inc. Prostate-specific antigen peptides and uses thereof
US20260123608A1 (en) 2024-08-06 2026-05-07 Regeneron Pharmaceuticals, Inc. Non-human animals having modified immunoglobulin heavy chain constant region locus and uses thereof
CN121896173A (zh) 2024-10-21 2026-04-21 深圳市湾岛细胞科技有限公司 表达外源肌苷单磷酸脱氢酶的真核细胞
WO2026096736A1 (en) 2024-10-31 2026-05-07 Regeneron Pharmaceuticals, Inc. Rodents expressing humanized polymeric immunoglobulin receptor

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US7041871B1 (en) * 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9020282D0 (en) 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
JP4157160B2 (ja) 1991-12-13 2008-09-24 ゾーマ テクノロジー リミテッド 改変抗体可変領域の調製のための方法
AU781922B2 (en) * 1991-12-17 2005-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0656064B1 (en) 1992-08-17 1997-03-05 Genentech, Inc. Bispecific immunoadhesins
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
PT1621554E (pt) 1992-08-21 2009-07-13 Univ Bruxelles Imunoglobtainas desprovidas de cadeias leves
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6838254B1 (en) 1993-04-29 2005-01-04 Conopco, Inc. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
US6080910A (en) 1997-02-20 2000-06-27 Case Western Reserve University Transgenic knockout animals lacking IgG3
US7083950B2 (en) 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
CN101498731A (zh) * 2000-05-18 2009-08-05 日本烟草产业株式会社 抗协同刺激信号转导分子ailim的人单克隆抗体及其药物用途
EP1311530A4 (en) 2000-08-03 2004-10-06 Wim-Van Schooten PRODUCTION OF HUMANIZED ANTIBODIES IN TRANSGENIC ANIMALS
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7235643B2 (en) 2000-11-07 2007-06-26 Morphotek, Inc. Antibodies and methods for generating genetically altered antibodies with high affinity
CN101016543A (zh) * 2000-11-17 2007-08-15 罗切斯特大学 筛选编码抗原特异性免疫球蛋白分子或其抗原特异性片段的多核苷酸的方法
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
AU2002319402B2 (en) 2001-06-28 2008-09-11 Domantis Limited Dual-specific ligand and its use
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
US7393648B2 (en) 2001-12-03 2008-07-01 Alexion Pharmaceuticals, Inc. Hybrid antibodies
BR0312276A (pt) 2002-06-28 2005-04-26 Centocor Inc Mimeticorpos ch1-removidos miméticos de epo de mamìfero, composições, métodos e usos
EP1600459A3 (en) 2002-06-28 2005-12-07 Domantis Limited Ligand
GB0228210D0 (en) 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
FR2861255B1 (fr) * 2003-10-24 2006-02-17 Centre Nat Rech Scient Mammifere non-humain transgenique pour la region constante de la chaine lourde des immunoglobulines humaines de classe a et ses applications.
WO2005070966A2 (en) 2004-01-16 2005-08-04 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
WO2005087177A2 (en) * 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Chimeric anti-vegf-d antibodies and humanized anti-vegf-d antibodies and methods of using same
EP1978032A3 (en) 2004-07-22 2009-02-18 Erasmus University Medical Center Rotterdam Binding molecules
WO2006044962A1 (en) 2004-10-19 2006-04-27 Regeneron Pharmaceuticals, Inc. Method for generating an animal homozygous for a genetic modification
US7462697B2 (en) 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
JP2008538912A (ja) 2005-04-29 2008-11-13 イナート・ファルマ 遺伝子導入動物および組換え抗体の製造方法
US10155816B2 (en) * 2005-11-28 2018-12-18 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
GB0618345D0 (en) * 2006-09-18 2006-10-25 Univ Erasmus Binding molecules
SG169348A1 (en) 2006-01-25 2011-03-30 Univ Erasmus Medical Ct Generation of heavy-chain only antibodies in transgenic animals
EP2005185B1 (en) * 2006-03-22 2010-10-20 Viral Logic Systems Technology Corp. Methods for identifying polypeptide targets
NZ587107A (en) 2006-06-02 2012-05-25 Regeneron Pharma High affinity antibodies to human il-6 receptor
GB0706628D0 (en) 2007-04-04 2007-05-16 Univ Erasmus Germ-line manipulation 1
CA2688834C (en) 2007-06-01 2020-01-07 Ronald Buelow Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies
BRPI0812465A2 (pt) 2007-06-08 2014-12-02 Dow Global Technologies Inc Expressão de fragmento de anticorpo solúvel por truncação de domínio ch1
WO2009013620A2 (en) 2007-06-11 2009-01-29 Erasmus University Medical Center Rotterdam Homologous recombination
RU2010113510A (ru) 2007-09-07 2011-10-20 Симфоген А/С (Dk) Способы рекомбинантной продукции антител против респираторно-цинцитиального вируса (rsv)
TWI476280B (zh) 2008-03-07 2015-03-11 Regeneron Pharma 來自二倍體宿主胚胎注射之ｅｓ－細胞衍生的老鼠
US20100122358A1 (en) 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
DK2509409T3 (en) * 2009-12-10 2016-11-14 Regeneron Pharma MICE, WHICH PRODUCES HEAVY CHAIN ANTIBODIES
JP6023667B2 (ja) * 2013-06-26 2016-11-09 矢崎総業株式会社 コネクタ
JP5602929B1 (ja) * 2013-11-08 2014-10-08 株式会社小松製作所 モータグレーダのリッパー装置およびこれを備えたモータグレーダ

Also Published As

Publication number Publication date
CY1121608T1 (el) 2020-05-29
US20150197553A1 (en) 2015-07-16
LT2509409T (lt) 2016-12-12
IL257822A (en) 2018-04-30
US12543713B2 (en) 2026-02-10
CY1118163T1 (el) 2017-06-28
KR20140024970A (ko) 2014-03-03
US11234419B2 (en) 2022-02-01
JP6293702B2 (ja) 2018-03-14
CA2782936A1 (en) 2011-06-16
SI2509409T1 (sl) 2016-12-30
US9888675B2 (en) 2018-02-13
AU2010328046C1 (en) 2018-01-18
HRP20190820T1 (hr) 2019-09-20
EP2509409B1 (en) 2016-07-27
JP5909449B2 (ja) 2016-04-26
SMT201900251T1 (it) 2019-07-11
ES2724975T3 (es) 2019-09-18
RU2603102C2 (ru) 2016-11-20
AU2010328046A1 (en) 2012-07-12
HUE043556T2 (hu) 2019-09-30
RU2012128856A (ru) 2014-01-20
KR101430514B1 (ko) 2014-08-19
TR201906488T4 (tr) 2019-05-21
WO2011072204A1 (en) 2011-06-16
CN110079550A (zh) 2019-08-02
ES2595376T3 (es) 2016-12-29
JP6271450B2 (ja) 2018-01-31
HUE030208T2 (en) 2017-04-28
DK2954779T3 (da) 2019-05-13
PT2509409T (pt) 2016-09-29
US20150196015A1 (en) 2015-07-16
DK2509409T3 (en) 2016-11-14
KR20130055556A (ko) 2013-05-28
EP2954779B1 (en) 2019-02-06
US20150197555A1 (en) 2015-07-16
JP2015133991A (ja) 2015-07-27
EP2509409A1 (en) 2012-10-17
KR101553244B1 (ko) 2015-09-15
PT2954779T (pt) 2019-05-29
SG181477A1 (en) 2012-07-30
PL2954779T3 (pl) 2019-07-31
RS58709B1 (sr) 2019-06-28
US20220201993A1 (en) 2022-06-30
LT2954779T (lt) 2019-05-27
JP2013513388A (ja) 2013-04-22
IL237818A (en) 2016-08-31
HK1220865A1 (en) 2017-05-19
US20110145937A1 (en) 2011-06-16
SG10201408181PA (en) 2015-01-29
SI2954779T1 (sl) 2019-06-28
JP2019141095A (ja) 2019-08-29
CN102711449B (zh) 2015-01-07
CN102711449A (zh) 2012-10-03
CA2782936C (en) 2019-06-18
EP2954779A1 (en) 2015-12-16
CN104131035A (zh) 2014-11-05
IL220150A0 (en) 2012-07-31
IL257822B (en) 2020-01-30
JP6615830B2 (ja) 2019-12-04
US20150197554A1 (en) 2015-07-16
PL2509409T3 (pl) 2017-02-28
HK1177100A1 (en) 2013-08-16
IL237819A (en) 2017-03-30
US20150197557A1 (en) 2015-07-16
JP2015077147A (ja) 2015-04-23
MY173363A (en) 2020-01-21
US20150197556A1 (en) 2015-07-16
AU2010328046B2 (en) 2014-07-31
US20140289876A1 (en) 2014-09-25
EP3504964A1 (en) 2019-07-03
US8754287B2 (en) 2014-06-17
JP2017140058A (ja) 2017-08-17

Similar Documents

Publication Publication Date Title
SG10201408181PA (en) Mice that make heavy chain antibodies
SG10201808225TA (en) Non-human animals that make single domain binding proteins
WO2007117410A3 (en) Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
EP4282879A3 (en) Use of fertile transgenic animals for producing antibodies bearing human variable regions
MX347322B (es) Ratones que expresan una cadena ligera con regiones constantes de raton y variables lambda humanas.
NZ629639A (en) Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
MX355726B (es) Ratones transgenicos que expresan moleculas quimericas del complejo mayor de histocompatibilidad (cmh) clase ii.
MX2020010763A (es) Ratones con complejo principal de histocompatibilidad modificado geneticamente.
MX2021000298A (es) Ratones con cadena ligera humanizada.
WO2013144566A3 (en) Animals expressing human lambda immunoglobulin light chain variable domain
SG194466A1 (en) Non-human animals expressing antibodies having a common light chain
SG10201408415PA (en) HUMANIZED FCγ R MICE
WO2009143472A3 (en) Method of generating single vl domain antibodies in transgenic animals
MX357623B (es) Ratones de cadena ligera universal humanizados.
EA201791127A1 (ru) Антитела, содержащие модифицированные константные участки тяжелой цепи
EP4635977A3 (en) Non-human animals having a humanized signal-regulatory protein gene
NZ627977A (en) Humanized rodents that express heavy chains containing vl domains
GEP20217311B (en) High affinity and aggregatively stable antibodies on basis of variable domains vl and derivative vhh
MX377146B (es) Ratones que expresan un repertorio limitado de cadena ligera de inmunoglobulina.
MX2013001401A (es) Anticuerpo anti-inmunoglobulina g1 humana.
AR110159A2 (es) Anticuerpo humano anti-tslp (linfopoyetina estromal tímica), y su empleo en el tratamiento de una afección inflamatoria relacionada con la tslp
GB201207814D0 (en) Human antibodies
HK1231692A1 (en) Non-human animals that make single domain binding proteins